Wong Chris Ho-Ming, Ko Ivan Ching-Ho, Leung David Ka-Wai, Siu Brian, Yuen Steffi Kar-Kei, Teoh Jeremy Yuen-Chun
S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Bladder Cancer. 2025 Jun 12;11(2):23523735251346569. doi: 10.1177/23523735251346569. eCollection 2025 Apr-Jun.
Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical cystectomy for select patients with muscle-invasive bladder cancer (MIBC). While each component of TMT plays a critical role, maximal TURBT is foundational to its success. This review examines the importance of maximal TURBT in optimizing oncological outcomes in TMT, discusses its technical nuances, and explores the evidence supporting its role in achieving durable local control and improving survival outcomes in MIBC.
三联疗法(TMT),包括膀胱肿瘤经尿道最大程度切除术(TURBT)后同步放化疗,已成为一种膀胱保留替代方案,用于特定的肌层浸润性膀胱癌(MIBC)患者,以替代根治性膀胱切除术。虽然TMT的每个组成部分都起着关键作用,但最大程度的TURBT是其成功的基础。本综述探讨了最大程度TURBT在优化TMT肿瘤学结局中的重要性,讨论了其技术细节,并探索了支持其在实现MIBC持久局部控制和改善生存结局方面作用的证据。